I-Mab: Dropping Coverage

Jay Lee Aug 17, 2023

Securities In This Article

We will discontinue analyst coverage of I-Mab IMAB on or about Sept. 15, 2023. We provide analyst research and ratings on over 1,500 companies globally and periodically adjust our coverage according to investor interest and staffing.

The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar’s editorial policies.

About the Author

View All Authors

Jay Lee

Senior Equity Analyst, Healthcare

I-Mab: Dropping Coverage

More in Stocks

Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?

Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains

After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?

About the Author

Jay Lee

Exact Sciences Earnings: Cologuard Continues to Grow at Strong Pace and Shares Undervalued

Takeda Pharmaceutical Earnings: Results in Line, Pipeline on Track, FVE Increased

Chugai Earnings: Slight Outperformance, Healthy Pipeline Progress, Shares Near Fair Value Estimate

Daiichi Sankyo: Out-Licensing Deal With Merck Reinforces Our View of Daiichi’s ADC Platform

Guardant Health: Reducing Fair Value Estimate on Liquid Biopsy Leader With Long Road to Profitability

Exact Sciences: Assuming Coverage With $78 Fair Value Estimate, as Robust Pipeline Not Yet Derisked

Innovent: We Are Positive on Its Slightly Dilutive Share Placement; Valuation Unchanged

WuXi Biologics: Interim Earnings Underwhelm but Fundamentals Remain Intact; Shares Undervalued

Innovent: Strong Interim Results; Valuation Lowered as a Result of Challenging Drug Pricing Outlook

CSPC Earnings: Interim Results Disappoint; Oncology Sales Weak; Valuation Lowered 19.8%

Sponsor Center

How we make money

How we use your personal data

How we approach editorial content